Abstract:Dosimetry of eye plaques for ocular tumors presents unique challenges in brachytherapy. The challenges in accurate dosimetry are in part related to the steep dose gradient in the tumor and critical structures that are within millimeters of radioactive sources. In most clinical applications, calculations of dose distributions around eye plaques assume a homogenous water medium and full scatter conditions. Recent Monte Carlo (MC)-based eye-plaque dosimetry simulations have demonstrated that the perturbation effects of heterogeneous materials in eye plaques, including the gold-alloy backing and Silastic insert, can be calculated with reasonable accuracy. Even additional levels of complexity introduced through the use of gold foil "seed-guides" and custom-designed plaques can be calculated accurately using modern MC techniques. Simulations accounting for the aforementioned complexities indicate dose discrepancies exceeding a factor of ten to selected critical structures compared to conventional dose calculations. Task Group 129 was formed to review the literature; re-examine the current dosimetry calculation formalism; and make recommendations for eye-plaque dosimetry, including evaluation of brachytherapy source dosimetry parameters and heterogeneity correction factors. A literature review identified modern assessments of dose calculations for Collaborative Ocular Melanoma Study (COMS) design plaques, including MC analyses and an intercomparison of treatment planning systems (TPS) detailing differences between homogeneous and heterogeneous plaque calculations using the American Association of Physicists in Medicine (AAPM) TG-43U1 brachytherapy dosimetry formalism and MC techniques. This review identified that a commonly used prescription dose of 85 Gy at 5 mm depth in homogeneous medium delivers about 75 Gy and 69 Gy at the same 5 mm depth for specific (125)I and (103)Pd sources, respectively, when accounting for COMS plaque heterogeneities. Thus, the adoption of heterogeneous dose calculation methods in clinical practice would result in dose differences >10% and warrant a careful evaluation of the corresponding changes in prescription doses. Doses to normal ocular structures vary with choice of radionuclide, plaque location, and prescription depth, such that further dosimetric evaluations of the adoption of MC-based dosimetry methods are needed. The AAPM and American Brachytherapy Society (ABS) recommend that clinical medical physicists should make concurrent estimates of heterogeneity-corrected delivered dose using the information in this report's tables to prepare for brachytherapy TPS that can account for material heterogeneities and for a transition to heterogeneity-corrected prescriptive goals. It is recommended that brachytherapy TPS vendors include material heterogeneity corrections in their systems and take steps to integrate planned plaque localization and image guidance. In the interim, before the availability of commercial MC-based brachytherapy TPS, it is recommended that clinical medical physicists use the line-source approximation in homogeneous water medium and the 2D AAPM TG-43U1 dosimetry formalism and brachytherapy source dosimetry parameter datasets for treatment planning calculations. Furthermore, this report includes quality management program recommendations for eye-plaque brachytherapy.

Dimebon as a Potential Therapy for Alzheimer's Disease

Early treatment and toxicity outcomes for small posterior uveal melanomas treated using custom loaded eye plaques

Effects Of Radioactive Iodine-125 Seed Implantation On Therapeutic Efficacy, Serum Vegf, Cea Levels, And Prognosis Of Patients With Ocular Malignant Tumors

Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS

Improved patient survival following surgery for coarctation of the aorta.

Apical dose versus volume dose of Ruthenium-106 brachytherapy for uveal melanoma

A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium‐103 and Iodine‐125 eye plaques

Dosimetric Investigation of Six Ru-106 Eye Plaques by EBT3 Radiochromic Films and Monte Carlo Simulation

CL115,347, an Analogue of Prostaglandin E2

Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity

Plaque Radiotherapy for Ocular Melanoma

Fundus image fusion in EYEPLAN software: an evaluation of a novel technique for ocular melanoma radiation treatment planning

Monte Carlo dosimetry of Y-90 and Ru-106 /Rh-106 disk sources for ocular melanoma treatment: beta dose falloff study

A practical method of estimating medium-heterogeneity corrected dose without a Monte Carlo calculation in ocular brachytherapy using 125I COMS plaques

Automatic dual air kerma strength treatment planning for focal low-dose-rate prostate brachytherapy boost using dosimetric and geometric constraints

Characterisation of the water/o-nitrophenyl octyl ether system in terms of the partition of nonelectrolytes and of ions.

The effect of intra- and inter-fractional motion on target coverage and margins in proton therapy for uveal melanoma

Selective dose escalation of regions suspicious for prostate cancer as identified by ultrasonic tissue-type imaging: dosimetric analysis of permanent Pd-103 prostate brachytherapy

High-Dose-Rate Yttrium-90 (90Y) Episcleral Plaque Brachytherapy for Iris and Iridociliary Melanoma

Feasibility of internal-source tracking with C-arm CT/SPECT imaging with limited-angle projection data for online in vivo dose verification in brachytherapy: A Monte Carlo simulation study

Current and Emerging Radiotherapy Options for Uveal Melanoma